Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom

Darshan Zala, MSc,* Iris Mosweu, MSc, Simone Critchlow, MSc, Renee Romeo, PhD, Paul McCrone, PhD

ABSTRACT

Objective: This study aims to cost and calculate the relative cost-effectiveness of the hypothetical suppression policies found in the Imperial College COVID-19 Response Team model.

Methods: Key population-level disease projections in deaths, intensive care unit bed days, and non-intensive care unit bed days were taken from the Imperial College COVID-19 Response Team report of March 2020, which influenced the decision to introduce suppression policies in the United Kingdom. National income loss estimates were from a study that estimated the impact of a hypothetical pandemic on the UK economy, with sensitivity analyses based on projections that are more recent. Individual quality-adjusted life-year (QALY) loss and costed resource use inputs were taken from published sources.

Results: Imperial model projected suppression policies compared to an unmitigated pandemic, even with the most pessimistic national income loss scenarios under suppression (10%), give incremental cost-effectiveness ratios below £50,000 per QALY. Assuming a maximum reduction in national income of 7.75%, incremental cost-effectiveness ratios for Imperial model projected suppression versus mitigation are below 60,000 per QALY.

Conclusions: Results are uncertain and conditional on the accuracy of the Imperial model projections; they are also sensitive to estimates of national income loss. Nevertheless, it would be difficult to claim that the hypothetical Imperial model–projected suppression policies are obviously cost-ineffective relative to the alternatives available. Despite evolving differences between government policy and Imperial model–projected suppression policy, it is hoped this article will provide some early insight into the trade-offs that are involved.

Keywords: COVID-19, coronavirus, suppression, mitigation, economic evaluation, cost-effectiveness, United Kingdom.

Introduction

Since the emergence of coronavirus disease 2019 (COVID-19) in December, the viral pandemic has spread from the Wuhan province in China across the globe, placing extraordinary demands on individuals, households, health systems, and every aspect of social and economic life.1 Global confirmed cases have now surpassed a million and confirmed deaths are over 180,000.2 In the United Kingdom there have been >130,000 confirmed cases with deaths (in and outside of hospitals) around 40,000 as of early June 2020.3 Most COVID-19 patients report mild symptoms and recover, with more serious infections skewed toward the elderly population and/or those with underlying conditions.1 These vulnerable patients are more susceptible to acute respiratory distress and the development of pneumonia within 3 to 6 weeks of infection.4,5 There is no known cure or vaccine for COVID-19, and although there may be some potentially effective pharmacological interventions, they have yet to be clinically validated. Governments have therefore introduced public health strategies that comprise a variety of nonpharmaceutical interventions (NPIs).6

Following the detection of the first case of COVID-19 in the United Kingdom in January 2020, UK government policy focused on containment with early detection and case isolation (eg, screening of arrivals from Wuhan province). In February 2020, the UK government introduced voluntary mitigation restrictions such as self-isolation for those with symptoms and social distancing advice for those most at risk.7 By the fourth week of March, official UK government policy could be described as a strategy of enforced suppression, defined as case isolation and home quarantine, general social distancing (including a social venue ban), and school and university closure.

The Imperial College COVID-19 Response Team report (Ferguson et al, 2020)8 and its projections published on March 16 are widely believed to have influenced the introduction of

* Address correspondence to: Darshan Zala, ZALA PRMA Limited, Brunel House, 340 Firecrest Court, Centre Park, Warrington, Cheshire WA1 1RG United Kingdom.
Email: darshanzala@hotmail.co.uk
1098-3015/36.00 - see front matter Copyright © 2020, ISPOR—The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.
suppression policies by the UK government. This study is an early economic evaluation of these hypothetical Imperial model–projected suppression policies and melds the rich outputs of the Imperial report with a model that estimated the impact of a hypothetical pandemic on the UK macroeconomy. It constitutes an exploratory or early economic evaluation for the following reasons: it is not informed by a de novo cost-utility model but is an analysis of the results of disparate models; and government policy may have been influenced by, but not fully reflect, Imperial model–projected suppression policy.

Methods

Hypothetical Imperial Model–Projected Suppression Policies

This analysis compares 2 versions of hypothetical but plausible suppression strategies to a mitigation policy and an unmitigated pandemic presented in Ferguson et al (2020). An unmitigated pandemic assumes no government control measures. The peak in deaths and intensive care unit (ICU) demand is predicted to occur by June 2020, with the latter being 30 times greater than the estimated surge capacity of 5000 ICU beds.

The aim of mitigation, which was official government policy until the third week of March, is to reduce the impact of the pandemic by flattening the curve to reduce peak ICU demand and overall deaths. This analysis is in line with Ferguson et al (2020) and assumes a policy involving the following 3 NPIs: individual case isolation, home quarantine (ie, quarantine of a household with a suspected case), and social distancing advice for people over 70 years of age. Further, that these policies are implemented for 3 months without pause (April to July 2020) and are predicted to reduce deaths by half and ICU peak by two-thirds relative to an unmitigated pandemic.

In suppression policy, the aim is to further flatten the curve and reduce ICU bed demand below surge capacity, by lowering the reproduction number (R) to 1 or below (ie, on average each new case generates 1 or fewer cases). Suppression involves the addition of more extensive controls to those implemented under mitigation, namely general social distancing and closure of schools and universities. The hypothetical suppression policies in this article assume alignment with Ferguson et al, and the 3 mitigation NPIs are expected to remain in place until late 2021 but social distancing and school/university closures are triggered conditional on ICU bed demand. Two suppression strategies are considered: (1) suppression 1, triggered “on” when there are 100 ICU cases in a week and “off” when weekly cases halve to 50 cases; (2) suppression 2, triggered “on” when there are 400 ICU cases in a week and “off” when weekly cases halve to 200 cases. Ferguson et al presented results for on triggers ranging from 60 to 400 ICU cases, and so the current analysis reflects the breadth of these plausible trigger scenarios. Current declared government suppression policy differs from these trigger scenarios, and the differences are discussed later.

Population-Level Disease Parameters

Ferguson et al used an individual-based simulation model to predict number infected, total deaths, cases that require critical care (ie, need admission to ICU), and cases that do not require critical care but require hospitalization (ie, non-ICU hospitalizations). Suitable quality-adjusted life-year (QALY) and costed resource use inputs were then applied to these projections. It was assumed that the infection was seeded in early January 2020 with a base-case reproduction number of $R_0 = 2.4$ (ie, on average each new case generates 2.4 more cases under unmitigated pandemic conditions). The proportion requiring hospitalization and critical care and the infection fatality ratio (IFR) varied by age based on early data. It was assumed that those hospitalized would need 8 (non-ICU) bed days; 30% of those hospitalized would require critical care constituting 10 ICU bed days and 6 (non-ICU) bed days (16 days total). Fifty percent of those in critical care die, and age-variant IFRs determine other deaths; these assumptions resulted in a UK-level IFR of 0.9% and hospitalization rate of 4.4%.

All population-level disease inputs (Table 1) for each of the strategies being evaluated are taken from the results of Ferguson et al for those corresponding to $R_0 = 2.4$. Total deaths are taken as directly reported in text and tables. Excess ICU bed days for the unmitigated and mitigated pandemic are calculated by digitizing the relevant curves and using area under the curve methods. For suppression 1, there is only a relevant curve for $R_0 = 2.2$ and so the area under the curve was calculated and adjusted to reflect $R_0 = 2.4$ using the ratio of peak ICU figures reported for both $R_0$ values. Excess hospitalization (non-ICU) bed days could then be calculated using assumptions about hospitalization reported in Ferguson et al.

Macroeconomic Parameters

Keogh-Brown et al (2010) used a macroeconomic model of the UK to quantify the impact of a hypothetical influenza pandemic on macroeconomic variables including gross domestic product (GDP). The modeled routes by which a pandemic could influence GDP were through a reduction in labor supply owing to death, illness (ie, direct absenteeism), school closures, and prophylactic absenteeism; consumption shocks owing to illness and precautionary avoidance; and modest investment deferment.

Keogh-Brown et al presented GDP loss scenarios for different pandemic severities and population behaviors. This article uses loss scenarios, for all interventions, consistent with a more severe disease: 50% of the population becoming infected, a working population mortality of 1.25%, and a 7-day average of direct absenteeism for those infected. The unmitigated pandemic assumes GDP loss consistent with 1 week of prophylactic absenteeism (PA) and no school closures (Table 1); the mitigation strategy, 4 weeks of PA and no school closures. Both suppression strategies assume GDP loss consistent with 4 weeks of PA, 13 weeks of school closures, and a more conservative precautionary consumption shock that raises 1-year GDP loss from 4.45% to 6.05%. Length of PA is varied, but under all scenarios it applies to 34% of the workforce (based on a survey and previous pandemic experience). These base-case national income loss inputs do not align perfectly with the current pandemic (and suppression policy) and so extensive income loss scenarios were conducted.

The UK national income was calculated to be £2.3 trillion as converted from current US dollars. For the scenario with QALY loss owing to unemployment, the workforce was assumed to be 32.6 million (Office for National Statistics). In this scenario, weeks of unemployment for the suppression strategies is based on the proportion of time social distancing and school/university closures are triggered.

Patient-Level QALY Loss and Costed Resource Use Parameters

All QALY sources used the EuroQol 5-dimension instrument, a descriptive system for quality of life comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Age-adjusted QALY loss associated with the average COVID-19 death was calculated by using age-varying QALYs (based on age group’s midpoints) and the most recent England and Wales lifetables, with weighting based on the IFR reported...
by age in Ferguson et al.8 Average QALY loss per ICU bed day16 and non-ICU bed day16,17 were applied in a way consistent with an economic evaluation of pneumonia in the United Kingdom.18 QALY loss owing to unemployment, based on a large Swedish quality-of-life study,19 was applied as a decrement of 9.6%, taking account of the age-adjusted average utility of the UK population.14

Average cost for an ICU bed day and a non-ICU bed day were taken from National Health Service (NHS) reference costs (XC06Z and XC07Z).20 End-of-life service costs corresponding to an inpatient emergency were taken from the Personal Social Services Research Unit21 and adjusted to 16 days. An Institute for Fiscal Studies analysis22 provided estimates of all inpatient healthcare costs (average per year) to death for different starting ages; using lifetables and weighting by Institute for Fiscal Studies, an average NHS healthcare saving could be calculated for each COVID-19 death. This accounts for 52% of total NHS hospital spending to death, and so this was adjusted upward to account for the remaining 48%.22,23

### Results

A full list of assumptions is provided in Appendix A for the purposes of model transparency (see Appendix A in Supplemental Materials found at https://doi.org/10.1016/j.jval.2020.07.001).24 The full breakdown of QALY loss by strategy, owing to COVID-19 deaths, ICU bed days for critical care patients, and (non-ICU) bed days are shown in Appendix B (see Appendix B in Supplemental Materials found at https://doi.org/10.1016/j.jval.2020.07.001). For all strategies, overwhelmingly most QALY loss is accounted for by deaths (≈ 99%), which is to be expected given the substantial average life-year loss per COVID-19 death. Total QALY loss is halved by mitigation (compared with an unmitigated pandemic) and then further reduced by 94% for suppression 1 and 82% for suppression 2. The scenario analysis including QALY loss owing to unemployment has a substantial impact on the Imperial model—projected suppression strategies—a 9-fold (4-fold) increase in QALY loss for suppression 1 (suppression 2)—attributable to the duration of unemployment spells.

For all strategies, most of the total cost is accounted for by national income loss, but the proportion it accounts for increases with more aggressive NPIs (and as hospitalization costs drop): 79% (unmitigated), 92% (mitigated), and almost 100% for both Imperial model—projected suppression strategies. Absolute national income loss increases 50% under mitigation and then is further doubled by suppression policies. Hospitalization (non-ICU) bed day costs are consistently double ICU bed day costs; healthcare savings from COVID-19 deaths are comparable to non-ICU bed day costs for all strategies.

Incremental total costs, QALY loss prevented, and incremental cost-effectiveness ratios (ICERs) do not vary greatly based on the

### Table 1. Summary of input parameters.

|                         | Unmitigated | Mitigated | Suppression 1 | Suppression 2 |
|-------------------------|-------------|-----------|---------------|---------------|
| **Population-level disease parameters** (Ferguson et al.8) |             |           |               |               |
| Total deaths*           | 510,000     | 255,000   | 15,000        | 46,000        |
| ICU bed days1           | 7,130,158   | 3,561,617 | 141,548       | 385,326       |
| Hospital (non-ICU) bed days3 | 17,587,724 | 8,785,321 | 349,152       | 950,470       |
| Macroeconomic parameters (Keogh-Brown et al1) |             |           |               |               |
| 1-year national income loss (%) | 1.84%       | 2.75%     | 6.05%         | 6.05%         |
| Workforce unemployed (%)9 |             |           |               |               |
| Weeks of unemployment§  |             |           |               |               |
| Patient-level QALY loss and costed resource use parameters |             |           |               |               |
| Average QALY loss due to COVID-19 death |             |           | 8.79882       |               |
| Average QALY loss for ICU bed day |             |           | 0.00110       |               |
| Average QALY loss for hospital (non-ICU) bed day |             |           | 0.00002       |               |
| Average QALY loss due to unemployment (per week)§ |     |           | 0.00161       |               |
| Average cost for ICU bed day |             |           | £1,152        |               |
| Average cost for hospital (non-ICU) bed day |             |           | £933          |               |
| Average (to death) healthcare saving due to COVID-19 death |             |           | £25,544       |               |
| Average cost for end-of-life care§ |             |           | £232          |               |

AUC indicates area under the curve; COVID-19, coronavirus disease 2019; ICU, intensive care unit; QALY, quality-adjusted life-years.

*For unmitigated and mitigated total deaths as reported in text. For both suppression strategies taken from Table 5.

†For unmitigated and mitigated calculated using AUCs in Figure 2. For suppression 1 AUC in Figure 4 gives deaths for R0 = 2.2 and so converted to R0 = 2.4 using peak ICU bed numbers in Table 4 and assuming proportionality between total ICU bed days and ICU peaks.

‡Calculated using Ferguson assumptions: 30% of those hospitalized need critical care (CC); CC patients have 10 ICU16 non-ICU bed days; other patients hospitalized have 8 non-ICU bed days.

§For scenario analyses only.

#1 and 4 weeks are taken from Keogh-Brown et al1 but 62 and 57 weeks based on % of time with social distancing in place reported in Table 4 of Ferguson et al.8
Imperial model—projected suppression policy being compared to the unmitigated or mitigated pandemic (Table 2). The addition of an end-of-life cost has virtually no impact.

The ICERs are roughly proportional to changes in national income loss. For example, if income loss has been underestimated by 50% for all strategies, ICERs are expected to increase by around 50%. Consistent with Ferguson et al, incremental results are relatively robust to changes in reproduction number (see Appendix C in Supplemental Materials found at https://doi.org/10.1016/j.jval.2020.07.001). Nevertheless, the results for R0 = 2.2 suggest that the cost-effectiveness of suppression strategy increases as the transmission potential of COVID-19 increases.

**Discussion**

This study aims to cost and calculate the relative cost-effectiveness of the hypothetical suppression policies found in the Imperial College COVID-19 Response Team model. For an economic evaluation to be meaningful, it must attempt to account for all the additional costs and health benefits associated with an intervention. For example, if the analysis had assumed an NHS perspective, the incremental analysis would show suppression strategy to be dominant (lower QALY loss and costs); but this would ignore the significant burden of costs that fall outside of the NHS budget that are required to achieve a reduction in deaths and hospitalizations (ie, national income loss).

The main strength of this evaluation is the use of population-level disease burden projections that are taken from a source that influenced the introduction of suppression policy by the UK government. Nevertheless, it is important to note that these are highly uncertain projections of hypothetical strategies; the various educated assumptions and inputs (eg, rates of compliance with NPI measures) must hold for the results of this economic evaluation to be valid. Reported COVID-19 deaths in the United Kingdom are already over the level projected under suppression 1 (15 000) and closer to those projected under suppression 2 (46

| Table 2. Results for base-case settings and scenario and sensitivity analyses (R = 2.4). |
|---------------------------------|----------------|----------------|----------------|----------------|
|                                 | Suppression 1 vs unmitigated | Suppression 1 vs mitigated | Suppression 2 vs unmitigated | Suppression 2 vs mitigated |
| Base-case                       |                              |                              |                              |                              |
| Incremental QALYs (ie, loss prevented) | 4, 363, 464 | 2, 115, 656 | 4, 090, 420 | 1, 842, 611 |
| Incremental costs               | £85, 756, 622, 748 | £70, 547, 645, 072 | £85, 806, 769, 566 | £70, 597, 791, 890 |
| Cost per additional QALY        | £19, 653 | £33, 346 | £20, 977 | £38, 314 |
| No death-related healthcare cost saving |                              |                              |                              |                              |
| Incremental QALYs (ie, loss prevented) | 4, 363, 464 | 2, 115, 656 | 4, 090, 420 | 1, 842, 611 |
| Incremental costs               | £73, 112, 468, 530 | £64, 417, 146, 057 | £73, 954, 471, 471 | £65, 259, 148, 998 |
| Cost per additional QALY        | £16, 756 | £30, 448 | £18, 080 | £35, 417 |
| Unemployment QALY loss included |                              |                              |                              |                              |
| Incremental QALYs (ie, loss prevented) | 3, 279, 950 | 1, 085, 781 | 3, 092, 729 | 898, 560 |
| Incremental costs               | £85, 756, 622, 748 | £70, 547, 645, 072 | £85, 806, 769, 566 | £70, 597, 791, 890 |
| Cost per additional QALY        | £26, 146 | £64, 974 | £27, 745 | £78, 568 |
| End-of-life cost included       |                              |                              |                              |                              |
| Incremental QALYs (ie, loss prevented) | 4, 363, 464 | 2, 115, 656 | 4, 090, 420 | 1, 842, 611 |
| Incremental costs               | £85, 641, 720, 407 | £70, 491, 934, 846 | £85, 699, 063, 129 | £70, 549, 277, 568 |
| Cost per additional QALY        | £19, 627 | £33, 319 | £20, 951 | £38, 288 |
| Net national income loss 50% less |                              |                              |                              |                              |
| Incremental QALYs (ie, loss prevented) | 4, 363, 464 | 2, 115, 656 | 4, 090, 420 | 1, 842, 611 |
| Incremental costs               | £37, 131, 122, 748 | £32, 432, 645, 072 | £37, 181, 269, 566 | £32, 482, 791, 890 |
| Cost per additional QALY        | £85, 10 | £15, 330 | £9, 090 | £17, 629 |
| Net national income loss 50% more |                              |                              |                              |                              |
| Incremental QALYs (ie, loss prevented) | 4, 363, 464 | 2, 115, 656 | 4, 090, 420 | 1, 842, 611 |
| Incremental costs               | £121, 737, 968, 530 | £102, 532, 146, 057 | £122, 579, 971, 471 | £103, 374, 148, 998 |
| Cost per additional QALY        | £27, 899 | £48, 464 | £29, 968 | £56, 102 |

QALY indicates quality-adjusted life-years.
The government fiscal package, estimated to cost around 3% of GDP (net of liabilities), is not intended to stimulate economic growth but has been described as a social insurance scheme. Therefore, it is assumed not to be an additional cost but to merely redistribute national income losses onto current and future taxpayers. It follows that there has been no adjustment for fiscal multiplier effects and the possible distortionary impacts of future changes in the tax system or monetary policy.

Cost-effectiveness invariably depends on views about the appropriate willingness-to-pay (WTP) threshold per QALY. A £20 000 to £30 000 per QALY threshold is used by NICE (£50 000 for end-of-life treatments); but this would assume national income loss only displaces other QALY-generating treatments funded from the NHS budget. More general estimates of the social value of a QALY suggest WTP thresholds of £10 000 to £70 000, and this is consistent with the threshold used by the Treasury and Department of Health (£60 000 per QALY). There will undoubtedly be substantial debate about what the relevant WTP threshold should be and even whether the pandemic constitutes a special case in which considerations of cost-effectiveness are less relevant (eg, Rule of Rescue).

Results are uncertain and conditional on the accuracy of the Imperial model projections, especially under the hypothetical suppression policies being evaluated. They are also sensitive to estimates of national income loss. This analysis suggests that even assuming more conservative national income loss scenarios (10% under suppression), ICERs for the Imperial model–projected suppression policy versus an unmitigated pandemic are below £50 000 per QALY. Assuming a maximum reduction in national income of 7.75% (ie, an incremental loss of 5% points), ICERs for Imperial model–projected suppression versus mitigation are below £60 000 per QALY. In conclusion, based on this preliminary analysis it would be difficult to claim that the hypothetical Imperial model–projected suppression policies are obviously cost-ineffective relative to the alternatives available. Despite evolving differences between government policy and Imperial model–projected suppression policy, it is hoped this article will provide some early insight into the trade-offs required in planning the eventual end to suppression policies in the United Kingdom, in particular the impact of individual cost and QALY components on relative cost-effectiveness.

Supplemental Material

Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.jval.2020.07.001.

Article and Author Information

Accepted for Publication: July 1, 2020
Published Online: August 27, 2020
doi: https://doi.org/10.1016/j.jval.2020.07.001

Author Affiliations: ZALA PRMA Limited, Warrington, UK (Zala); Department of Health Policy, Cowdray House, London School of Economics and Political Science, London, UK (Mosweu); Delta Hat Limited, Long Eaton, UK (Critchlow); Department of Health Service and Population Research, Institute of Psychiatry, Psychology & Neuroscience, King’s College, London, UK (Romeo); Centre for Mental Health, Institute for Lifecourse Development, University of Greenwich, London, UK (McCrone).

Author Contributions: Concept and design: Zala, Mosweu, Critchlow, Romeo

Acquisition of data: Zala, Mosweu, Critchlow

Analysis and interpretation of data: Zala, Critchlow, McCrone

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Drafting of the manuscript: Zala, Mosweu, Critchlow
Critical revision of the paper for important intellectual content: Zala, Critchlow, Romeo, McCrone
Statistical analysis: Zala
Administrative, technical, or logistic support: Zala
Supervision: Zala, Romeo, McCrone

Conflict of Interest Disclosures: The authors reported no conflicts of interest.

Funding/Support: The authors received no financial support for this research.

REFERENCES

1. Chen T-M, Rui J, Wang Q-P, Zhao Z-Y, Cui J-A, Yin L. A mathematical model for simulating the phase-based transmissibility of a novel coronavirus. Infect Dis Poverty. 2020;9(1):24.

2. Johns Hopkins University. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE). https://coronavirus.jhu.edu/map.html. Accessed April 18, 2020.

3. UK government. Coronavirus cases in the UK: daily updated statistics. https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public. Accessed April 11, 2020.

4. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506–510.

5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.

6. Flaxman S, Mishra S, Gandy A, et al. Estimating the number of infections and the impact of nonpharmaceutical interventions on COVID-19 in 11 European countries. Nature. 2020;584:257–261.

7. British Foreign Policy Group. COVID-19 timeline. https://bfpg.co.uk/2020/04/covid-19-timeline/. Accessed April 13, 2020.

8. Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gd2-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf. Accessed March 23, 2020.

9. Keogh-Brown MR, Wren-Lewis S, Edmunds WJ, Beutels P, Smith RD. The possible macroeconomic impact on the UK of an influenza pandemic. Health Econ. 2010;19:1345–1360.

10. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448–452.

11. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of COVID-19 disease. medRxiv. https://www.medrxiv.org/content/10.1101/2020.03.09.20033575v1. 2020.

12. The World Bank. GDP (current US$). https://data.worldbank.org/country/united-kingdom. Accessed April 1, 2020.

13. Office for National Statistics. Employment in the UK: August 2019. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/employmentandemployeetypes/bulletins/employmentintheuk/august2019. Accessed April 4, 2020.

14. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518.

15. Office for National Statistics. National life tables: England and Wales. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesenglandandwalesreferencecites. Accessed April 4, 2020.

16. Kind P, Hardman G, Maccou S. UK population norms for EQ-5D. Discussion Paper 172. University of York, Centre for Health Economics; 1999.

17. Edelstein JM, White P, Guthrie E. Survival, morbidity, and quality of life after discharge from intensive care. Crit Care Med. 2000;28:2293–2299.

18. Edwards SJ, Wordsworth S, Clarke MJ. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost–utility analysis comparing meropenem with piperacillin/tazobactam. Eur J Health Econ. 2012;13(2):181–192.

19. Norström F, Waerelund A, Lindholm L, et al. Does unemployment contribute to poorer health-related quality of life among Swedish adults? BMC Public Health. 2019;19:457.

20. National Health Service. National cost collection for the NHS. https://improvement.nhs.uk/resources/national-cost-collection/. Accessed April 7, 2020.

21. Personal Social Services Research Unit. Unit costs of health and social care 2019. https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/. Accessed March 30, 2020.

22. Lee T, Stoye G. Variation in end-of-life hospital spending in England: evidence from linked survey and administrative data. Institute for Fiscal Studies Working Paper W19/22. 2019.

23. NHS Improvement. Reference costs 2017/18: highlights, analysis and introduction to the data. London, UK: NHS Improvement; 2018.

24. Sampson CJ, Arnold R, Bryan S, et al. Transparency in decision modelling: what, why, who and how? Pharmacoeconomics. 2019;37:1355–1369.

25. Loureiro J, Paton R, Ghafar J, et al. Fundamental principles of epidemiological spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic. Medrxiv. 2020.

26. KPMG. Economic Outlook March 2020. What is the likely impact of COVID-19 on the economy? https://home.kpmg/uk/en/home/insights/2020/03/uk-economic-outlook.html?utm_medium=vanity_url. Accessed April 9, 2020.

27. National Institute of Economic and Social Research. National Institute monthly GDP tracker. https://www.niesr.ac.uk/sites/default/files/publications/GDPtracker20.pdf. Accessed April 9, 2020.

28. PricewaterhouseCoopers. COVID-19 UK Economic Update. https://www.pwc.co.uk/premium/covid-19/uk-economic-update-covid-19.pdf. Accessed April 9, 2020.

29. Morgan Stanley. Coronavirus: recession, response, recovery. https://www.morganstanley.com/ideas/coronavirus-impact-on-global-growth. Accessed April 9, 2020.

30. Office for Budget Responsibility. April update. https://obr.uk/coronavirus-reference-scenario/. Accessed April 9, 2020.

31. Institute for Fiscal Studies. The economic response to coronavirus will substantially increase government borrowing. https://www.ifs.org.uk/publications/14771. Accessed April 9, 2020.

32. National Institute for Health and Care Excellence. Center for Health Technology Evaluation. Consultation paper: Value based assessment of health technologies. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/VBA-TA-Methods-Guide-for-Consultation.pdf. Accessed April 9, 2020.

33. Donaldson C, Baker R, Mason H, et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res. 2011;11:8.

34. National Health Service. National cost collection for the NHS. https://improvement.nhs.uk/resources/national-cost-collection/. Accessed April 7, 2020.

35. Personal Social Services Research Unit. Unit costs of health and social care 2019. https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/. Accessed March 30, 2020.

36. Ofﬁce for Budget Responsibility. April update. https://obr.uk/coronavirus-reference-scenario/. Accessed April 9, 2020.

37. Institute for Fiscal Studies. The economic response to coronavirus will substantially increase government borrowing. https://www.ifs.org.uk/publications/14771. Accessed April 9, 2020.

38. National Institute for Health and Care Excellence. Center for Health Technology Evaluation. Consultation paper: Value based assessment of health technologies. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/VBA-TA-Methods-Guide-for-Consultation.pdf. Accessed April 9, 2020.

39. Donaldson C, Baker R, Mason H, et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res. 2011;11:8.

40. HM Treasury. The Green Book: central government guidance on appraisal and evaluation. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/685903/The_Green_Book.pdf. Accessed April 10, 2020.

41. Glover D, Henderson J. Quantifying health impacts of government policies: a how-to guide to quantifying the health impacts of government policies. Department of Health. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/216003/dh_120108.pdf.

42. Orr S, Wolff J. Reconciling cost-effectiveness with the rule of rescue: the institutional division of moral labour. Theory Soc. 2015;78:525–538.